Efficacy and Tolerability of Cancer Pain Management with Controlled-release Oxycodone Tablets in Opioid-naive Cancer Pain Patients, Starting with 5 mg Tablets

Koizumi, Wasaburo; Toma, Hiroshi; Watanabe, Kenichi; Katayama, Kanji; Kawahara, Mutsuto; Matsui, Kaoru; Takiuchi, Hiroya; Yoshino, Kunitoshi; Araki, Nobuhito; Kodama, Ken; Kimura, Hideyuki; Kono, Ichiro; Hasegawa, Hiroyasu; Hatanaka, Kenji; Hiraga, Kenji; Takeda, Fumikazu

doi:10.1093/jjco/hyh104

Cited by 45 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxycodone is currently most used as an opioid analgesic for moderate to severe cancer-related pain in Japan, so patients given oxycodone for the first time were included. 9 This study was performed with the approval of the Ethics Review Boards of Kyoto Prefectural University of Medicine.…”

Section: Introductionmentioning

confidence: 99%

Predictive Factors for Nausea or Vomiting in Patients with Cancer Who Receive Oral Oxycodone for the First Time: Is Prophylactic Medication for Prevention of Opioid-Induced Nausea or Vomiting Necessary?

Kanbayashi

Hosokawa

2014

Journal of Palliative Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Predictive Factors for Nausea or Vomiting in Patients with Cancer Who Receive Oral Oxycodone for the First Time: Is Prophylactic Medication for Prevention of Opioid-Induced Nausea or Vomiting Necessary?

Kanbayashi

Hosokawa

2014

Journal of Palliative Medicine

View full text Add to dashboard Cite

show abstract

“…Five open-label studies on oxycodone and cancer pain were also identified (table 2) [18,19,20,21,22]. The total number of patients followed by these studies was 608.…”

Section: Resultsmentioning

confidence: 99%

Oxycodone and the Challenge of Neuropathic Cancer Pain: A Review

Olarte

2008

Oncology

View full text Add to dashboard Cite

In order to evaluate the potential role of oxycodone in cancer pain management, neuropathic cancer pain was selected as a model for difficult pain syndromes. A nonsystematic, yet exhaustive, review of the literature provided the relevant evidence for the discussion. Ten randomized controlled trials (RCTs) and 5 open-label studies on oxycodone and cancer pain, 3 RCTs and 1 open-label study on oxycodone and neuropathic pain, and 2 RCTs on oxycodone and visceral pain were identified and reviewed. Additionally, 5 basic research studies that contributed to our knowledge of the specific mechanisms of action of oxycodone were also reviewed. Finally, recent evidence-based reviews of RCTs on neuropathic pain were selected (6 reviews), and specific RCTs on neuropathic cancer pain were also identified (2 trials). The review of the literature shows that the management of neuropathic cancer pain has changed dramatically in the last few years thanks to new approaches and novel drugs. The vast majority of these new drugs have been proven to be useful in ‘benign’ neuropathic pain syndromes. The intrinsic difficulties in performing RCTs in cancer pain have traditionally justified the acceptance of drugs already known to be effective in benign neuropathic pain, in spite of insufficient evidence in malignant neuropathic pain. Therefore, a case is made for the development of specific guidelines for the management of both simple and complex cases of neuropathic cancer pain. An example of one of such clinical guidelines is provided, in which the role of oxycodone is particularly relevant given the existing evidence.

show abstract

“…Minimising AEs at the beginning of treatment is important for allowing patients to develop tolerance towards the side eff ects, prior to increasing the dose to provide optimal analgesia. Other studies suggest it may be useful to begin a treatment regimen with a low starting dose, and follow it with a slow titration period [25,26]. Th is may be especially important in patients that can be predicted to have specifi c problems with tolerability, such as opioid-naïve or elderly patients.…”

Section: Discussionmentioning

confidence: 99%

Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses

Ringe

Schäfer

Wimmer

et al. 2011

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

Efficacy and Tolerability of Cancer Pain Management with Controlled-release Oxycodone Tablets in Opioid-naive Cancer Pain Patients, Starting with 5 mg Tablets

Cited by 45 publications

References 16 publications

Predictive Factors for Nausea or Vomiting in Patients with Cancer Who Receive Oral Oxycodone for the First Time: Is Prophylactic Medication for Prevention of Opioid-Induced Nausea or Vomiting Necessary?

Predictive Factors for Nausea or Vomiting in Patients with Cancer Who Receive Oral Oxycodone for the First Time: Is Prophylactic Medication for Prevention of Opioid-Induced Nausea or Vomiting Necessary?

Oxycodone and the Challenge of Neuropathic Cancer Pain: A Review

Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses

Contact Info

Product

Resources

About